238 related articles for article (PubMed ID: 35917118)
1. Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
Proietti E; Pauwels RWM; van der Woude CJ; Doukas M; Oudijk L; Peppelenbosch MP; Grohmann U; Crombag MBS; de Vries AC; Fuhler GM
Inflamm Bowel Dis; 2023 Jul; 29(7):1038-1046. PubMed ID: 35917118
[TBL] [Abstract][Full Text] [Related]
2. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
[TBL] [Abstract][Full Text] [Related]
3. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
[TBL] [Abstract][Full Text] [Related]
7. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study.
Gómez Espín R; Nicolás De Prado I; Gil Candel M; González Carrión M; Rentero Redondo L; Iniesta Navalón C
Rev Esp Enferm Dig; 2021 Feb; 113(2):110-115. PubMed ID: 33213170
[TBL] [Abstract][Full Text] [Related]
8. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
[TBL] [Abstract][Full Text] [Related]
9. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
[TBL] [Abstract][Full Text] [Related]
10. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
[TBL] [Abstract][Full Text] [Related]
11. Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease.
Bertin L; Barberio B; Gubbiotti A; Bertani L; Costa F; Ceccarelli L; Visaggi P; Bodini G; Pasta A; Sablich R; Urbano MT; Ferronato A; Buda A; De Bona M; Del Corso G; Massano A; Angriman I; Scarpa M; Zingone F; Savarino EV
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541765
[No Abstract] [Full Text] [Related]
12. Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients.
Mechie NC; Burmester M; Mavropoulou E; Pilavakis Y; Kunsch S; Ellenrieder V; Amanzada A
Medicine (Baltimore); 2021 Mar; 100(11):e25111. PubMed ID: 33725990
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
[No Abstract] [Full Text] [Related]
14. [Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease].
Wu Y; Xu Y; Zhang G; Zhang Y; Wang J; You P; Peng T; Liu Y; Chen N
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):253-259. PubMed ID: 38595241
[TBL] [Abstract][Full Text] [Related]
15. Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease.
Pan Y; Ahmed W; Mahtani P; Wong R; Longman R; Jeremy Lukin D; Scherl EJ; Battat R
Inflamm Bowel Dis; 2022 Dec; 28(12):1865-1871. PubMed ID: 35212368
[TBL] [Abstract][Full Text] [Related]
16. Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn's disease.
Pauwels RWM; Ten Bokkel Huinink S; van der Woude CJ; Doukas M; Oudijk L; de Vries AC
Scand J Gastroenterol; 2023; 58(9):980-987. PubMed ID: 36970968
[TBL] [Abstract][Full Text] [Related]
17. Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis.
Alsoud D; De Hertogh G; Compernolle G; Tops S; Sabino J; Ferrante M; Thomas D; Vermeire S; Verstockt B
J Crohns Colitis; 2022 Nov; 16(10):1562-1570. PubMed ID: 35533353
[TBL] [Abstract][Full Text] [Related]
18. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
[No Abstract] [Full Text] [Related]
19. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
20. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
